

Revision date: 13-Dec-2007

Version: 1.4

Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Emergency telephone number:CHEMTREC (24 hours): 1-800-424-9300Contact E-Mail:pfizer-MSDS@pfizer.com

Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Cetirizine HCI Film Coated Tablets

Trade Name:	ZYRTEC®
Chemical Family:	Mixture
Intended Use:	Pharmaceutical product used as antihistamine

2. HAZARDS IDENTIFICATION

Appearance:	White, film-coated tablet
Statement of Hazard:	Non-hazardous in accordance with international standards for workplace safety.
Additional Hazard Information: Short Term:	Active ingredient may be harmful if swallowed. Accidental ingestion may cause effects similar to those seen in clinical use.
Long Term: Known Clinical Effects: EU Indication of danger:	Repeat-dose studies in animals have shown a potential to cause adverse effects on liver. Sleepiness, dry mouth, fatigue, pharyngitis, dizziness Not classified
Australian Hazard Classification (NOHSC):	Non-Hazardous Substance. Non-Dangerous Goods.
Note:	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Material Name: Cetirizine HCI Film Coated Tablets Revision date: 13-Dec-2007

Hazardous				
Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	*
Colloidal silicon dioxide	7631-86-9	231-545-4	Not Listed	*
		EEC No. 418-260-2		
Magnesium stearate	557-04-0	209-150-3	Not Listed	*
Cetirizine hydrochloride	83881-52-1	Not listed	Xn;R22	5.88
Titanium dioxide	13463-67-7	236-675-5	Not Listed	*
Polyethylene glycol	25322-68-3	Not listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Croscarmellose sodium	74811-65-7	Not listed	Not Listed	*
Lactose	63-42-3	200-559-2	Not Listed	*
Hypromellose	9004-65-3	Not listed	Not Listed	*

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
Symptoms and Effects of Exposure:	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media:	Use carbon dioxide, dry chemical, or water spray.
Hazardous Combustion Products:	May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride and other chlorine-containing compounds.
Fire Fighting Procedures:	Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Evacuate area and fight fire from a safe distance.
Fire / Explosion Hazards:	Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (
	Section 8). Minimize exposure.		

Material Name: Cetirizine HCI Film Coated Tablets Revision date: 13-Dec-2007

Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.	
Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.	
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.	
7. HANDLING AND STORAGE		
General Handling:	Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Releases to the environment should be avoided.	

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Microcrystalline cellulose	
ACGIH Threshold Limit Value (TWA)	= 10 mg/m³ TWA
Australia TWA	= 10 mg/m³ TWA
Belgium OEL - TWA	= 10 mg/m³ TWA
Estonia OEL - TWA	= 10 mg/m³ TWA
France OEL - TWA	= 10 mg/m ³ VME
Ireland OEL - TWAs	= 10 mg/m³ TWA
	= 4 mg/m³ TWA
Latvia OEL - TWA	= 2 mg/m³ TWA
OSHA - Final PELS - TWAs:	= 15 mg/m ³ TWA total
	$= 5 \text{ mg/m}^3 \text{ TWA}$
Portugal OEL - TWA	$= 10 \text{ mg/m}^3 \text{ TWA}$
Romania OEL - TWA	$= 10 \text{ mg/m}^3 \text{ TWA}$
Spain OEL - TWA	= 10 mg/m ³ VLA-ED
Colloidal silicon dioxide	
Australia TWA	= 2 mg/m³ TWA
Austria OEL - MAKs	= 4 mg/m ³ MAK
Czech Republic OEL - TWA	= 0.1 mg/m ³ TWA
	= 4.0 mg/m ³ TWA
Estonia OEL - TWA	= 2 mg/m³ TWA
Germany - TRGS 900 - TWAs	= 4 mg/m³ TWA
Ireland OEL - TWAs	= 2.4 mg/m ³ TWA
	$= 6 \text{ mg/m}^3 \text{ TWA}$
Latvia OEL - TWA	= 1 mg/m ³ TWA containing more than 70% SiO2 (quartz)
	= 2 mg/m ³ TWA containing 10-70% SiO2 (granite, mica)
OSHA - Final PELs - Table Z-3 Mineral D:	= 4 mg/m ³ TWA containing 2-10% SiO2 (copper sulfate ores)
OSHA - FINALPELS - TADIE 2-3 Mineral D.	(80)/(% SiO2) mg/m³ TWA = 20 mppcf TWA
Slovakia OEL - TWA	= $4.0 \text{ mg/m}^3 \text{ TWA}$
Slovenia OEL - TWA	$= 4 \text{ mg/m}^3 \text{ TWA}$

Material Name: Cetirizine HCI Film Coated Tablets Revision date: 13-Dec-2007

Magnesium stearate	
ACGIH Threshold Limit Value	
Australia TWA	= 10 mg/m ³ TWA
Belgium OEL - TWA	= 10 mg/m³ TWA
Ireland OEL - TWAs	= 10 mg/m ³ TWA except lead stearate
Lithuania OEL - TWA	= 3 mg/m ³ IPRV
Portugal OEL - TWA	= 10 mg/m ³ TWA does not include stearates of toxic metals
Spain OEL - TWA	= 10 mg/m ³ VLA-ED not including stearates of toxic metals
Sweden OEL - TWAs	= 5 mg/m ³ LLV
Cetirizine hydrochloride	
Pfizer OEL TWA-8 Hr:	150µg/m³
Titanium dioxide	
ACGIH Threshold Limit Value	
Australia TWA	= 10 mg/m ³ TWA
Austria OEL - MAKs	= 6 mg/m ³ MAK
Belgium OEL - TWA	= 10 mg/m ³ TWA
Bulgaria OEL - TWA	= 10.0 mg/m³ TWA
Denmark OEL - TWA	= 6 mg/m³ TWA
Estonia OEL - TWA	= 5 mg/m³ TWA
France OEL - TWA	= 10 mg/m ³ VME
Greece OEL - TWA	= 10 mg/m³ TWA
	= 5 mg/m ³ TWA
Ireland OEL - TWAs	= 10 mg/m³ TWA
	= 4 mg/m³ TWA
Latvia OEL - TWA	= 10 mg/m ³ TWA
Lithuania OEL - TWA	= 5 mg/m ³ IPRV
Netherlands OEL - TWA	= 10 mg/m ³ MAC
OSHA - Final PELS - TWAs:	= 15 mg/m ³ TWA total
Poland OEL - TWA	= 10.0 mg/m ³ NDS <2% free crystalline silica and containing no
	asbestos
Portugal OEL - TWA	= 10 mg/m³ TWA
Romania OEL - TWA	= 10 mg/m³ TWA
Spain OEL - TWA	= 10 mg/m ³ VLA-ED
Sweden OEL - TWAs	= 5 mg/m ³ LLV
Polyothylana glycol	
Polyethylene glycol Austria OEL - MAKs	$-1000 \text{ mg/m}^3 \text{MAK}$
	= 1000 mg/m ³ MAK = 1000 mg/m ³ TM/A
Germany - TRGS 900 - TWAs Netherlands OEL - TWA	= 1000 mg/m ³ TWA = 1000 mg/m ³ MAC
Slovakia OEL - TWA	$= 1000 \text{ mg/m}^3 \text{ TWA}$
Slovenia OEL - TWA	= 1000 mg/m ³ TWA
The exposure limit(s) listed for solid co	mponents are only relevant if dust may be generated.
Analytical Method:	Analytical method available for cetirizine hydrochloride. Contact Pfizer Inc for further information.
Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	

Material Name: Cetirizine HCI Film Coated Tablets Revision date: 13-Dec-2007

Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eves:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:	Tablet	Color:	White
Molecular Formula:	Mixture	Molecular Weight:	Mixture

10. STABILITY AND REACTIVITY

Stability:	Stable
Conditions to Avoid:	Heat, sparks, and flame
Incompatible Materials:	Bases, strong oxidizers

Will not occur

Polymerization:

11. TOXICOLOGICAL INFORMATION

General Information:

The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Cetirizine hydrochloride

Rat (M) Oral LD50 703 mg/kg Rat (F) Oral LD50 865 mg/kg

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg Rabbit Dermal LD50 > 2000 mg/kg

Lactose

Rat Oral LD50 > 10 g/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg Rat Inhalation LC50 > 2000 mg/m³

Titanium dioxide

Rat Oral LD50 > 7500 mg/kg Rat Subcutaneous LD 50 50 mg/kg

Hypromellose

Rat Oral LD50 > 10,000 mg/kg

Material Name: Cetirizine HCI Film Coated Tablets Revision date: 13-Dec-2007

Acute Toxicity Comments:	A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable
	at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating Eye Irritation Rabbit Non-irritating

Polyethylene glycol

Eye Irritation Rabbit Mild Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Cetirizine hydrochloride

6 Month(s)	Dog	Oral 8 mg/kg/day	NOEL	None identified
1 Month(s)	Dog	Oral 45 mg/kg/day	NOEL	None identified
6 Month(s)	Rat	Oral 8 mg/kg/day	NOEL	Liver
1 Year(s)	Monkey	/ Oral 45 mg/kg/da	ay NOA	EL None identified
1 Year(s)	Dog	Oral 60 mg/kg/day	NOAEL	None identified

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Cetirizine hydrochloride

Reproductive & Fertility Mouse Oral 64 mg/kg/day NOAEL No effects at maximum dose Not Teratogenic Embryo / Fetal Development Oral 96 mg/kg/day Mouse NOAEL Embryo / Fetal Development Oral 225 mg/kg/day Rat NOAEL Not Teratogenic Embryo / Fetal Development Rabbit Oral 135 mg/kg/day NOAEL Not Teratogenic Peri-/Postnatal Development Mouse No route specified 24 mg/kg/day NOEL Maternal Toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Cetirizine hydrochloride

Bacterial Mutagenicity (Ames)BacteriaNegativeChromosome AberrationHuman LymphocytesNegativeIn Vivo MicronucleusRatNegativeChromosome AberrationMouse LymphomaNegative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Cetirizine hydrochloride 2 Year(s) Rat Oral 20 mg/kg/day NO

2 Year(s) Rat Oral 20 mg/kg/day NOEL Not carcinogenic 2 Year(s) Mouse Oral 4 mg/kg/day NOEL Not carcinogenic, Benign tumors

Carcinogen Status:	None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below
Colloidal silicon dioxide IARC:	Group 3
Titanium dioxide IARC: OSHA:	Group 2B Present

Material Name: Cetirizine HCI Film Coated Tablets Revision date: 13-Dec-2007

12. ECOLOGICAL INFORMATION

Environmental Overview:

The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Cetirizine hydrochloride

Pseudokirchneriella subcapitata (Green Alga)NPDESEC5096Hours96.9mg/LDaphnia magna (Water Flea)NPDESLC5048Hours14mg/LCyprinodon variegatus (Sheepshead Minnow)NPDESLC5048Hours> 100mg/LMysidopsis bahia (Mysid Shrimp)NPDESLC5048Hours44.7mg/LPimephales promelas (Fathead Minnow)NPDESLC5048Hours> 100mg/L

Bacterial Inhibition: (Species, Method, End Point, Duration, Result)

Cetirizine hydrochloride Activated sludge MIC 100 mg/L

13. DISPOSAL CONSIDERATIONS

Disposal Procedures:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger:

Not classified

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

Material Name: Cetirizine HCI Film Coated Tablets Revision date: 13-Dec-2007

WHMIS hazard class: None required This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.		
Microcrystalline cellulose Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	XU Present 232-674-9	
Croscarmellose sodium Australia (AICS):	Present	
Colloidal silicon dioxide Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Present Present 231-545-4 EEC No. 418-260-2	
Lactose Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Present Present 200-559-2	
Magnesium stearate Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Present Present 209-150-3	
Titanium dioxide Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Present Present 236-675-5	
Hypromellose Inventory - United States TSCA - Sect. 8(b) Australia (AICS): Standard for the Uniform Scheduling for Drugs and Poisons:	XU Present Schedule 4	
Polyethylene glycol Inventory - United States TSCA - Sect. 8(b) Australia (AICS):	XU Present	

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed. **Data Sources:**

Publicly available toxicity information. Safety data sheets for individual ingredients. Pfizer proprietary drug development information.

Material Name: Cetirizine HCI Film Coated Tablets Revision date: 13-Dec-2007

Reasons for Revision:	Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 15 - Regulatory Information.
Prepared by:	Toxicology and Hazard Communication Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

End of Safety Data Sheet